UM Miller School of Medicine: Repurposed Drug Shrinks NF2-Related Schwannomatosis Tumors
June 22, 2024
June 22, 2024
MIAMI, Florida, June 22 (TNSres) -- The University of Miami's Miller School of Medicine issued the following news on June 21, 2024:
By Lisette Hilton
Researchers from major centers around the world that treat and study neurofibromatosis type 2 (NF2)-related schwannomatosis, including the University of Miami Miller School of Medicine, have promising evidence that the approved lung cancer drug, brigatinib, may shrink tumors associated with this progressive genetic sy . . .
By Lisette Hilton
Researchers from major centers around the world that treat and study neurofibromatosis type 2 (NF2)-related schwannomatosis, including the University of Miami Miller School of Medicine, have promising evidence that the approved lung cancer drug, brigatinib, may shrink tumors associated with this progressive genetic sy . . .